Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer (original) (raw)

Cancer immunotherapy: present scenarios and the future of immunotherapy

Gaurisankar Sa

The Nucleus, 2019

View PDFchevron_right

Immunotherapy: A Novel Approach to Fight Cancer

Fateh Singh

International Journal of Current Microbiology and Applied Sciences, 2020

View PDFchevron_right

Immune dysregulation in cancer patients developing immune-related adverse events

Shaheen Banu Khan

British Journal of Cancer, 2018

View PDFchevron_right

Anticancer Immunotherapy in Combination with Proapoptotic Therapy

B. Gjertsen

Current Cancer Drug Targets, 2008

View PDFchevron_right

1335: 21% Five-Year Survival in High Risk Metastatic Renal Cell Carcinoma Patients on Inhaled Interleukin-2: A German Outcome Study

Edith Huland

The Journal of Urology, 2005

View PDFchevron_right

Immunotherapy/Biological Therapies

iwan sumantri

Neuro-Oncology, 2013

View PDFchevron_right

Interleukin 2 receptor—A target for immunosuppressive therapy

Michael Shapiro

Transplantation Reviews, 1987

View PDFchevron_right

Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients

Kosei Yasumoto

Cancer Immunology, Immunotherapy, 1996

View PDFchevron_right

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

Brendon Coventry

Cancer Management and Research, 2012

View PDFchevron_right

Human Interleukin 2 (IL-2) Promotion of Immune Regulation and ClinicalOutcomes: A Review

Claudia Regina Bonini Domingos

Journal of Cytokine Biology, 2016

View PDFchevron_right

Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

Laura Ridolfi

Cancer Immunology, Immunotherapy, 1998

View PDFchevron_right

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Max Hardy-Werbin

OncoImmunology, 2019

View PDFchevron_right

Cells and Cytokines in Lung Inflammation

Marina Pretolani

Mediators of Inflammation, 1994

View PDFchevron_right

The dark side of immunotherapy

Nwanneka Okwundu

Annals of Translational Medicine, 2021

View PDFchevron_right

Efficacy of multiple anticancer therapies may depend on host immune response

Kritika Karri

Advances in Science, Technology and Engineering Systems Journal, 2017

View PDFchevron_right

Immune system: a double-edged sword in cancer

Lakshmi Narendra

Inflammation Research, 2013

View PDFchevron_right

Innate immune cells for immunotherapy of autoimmune and cancer disorders

Gabriel Ascui

International Reviews of Immunology, 2017

View PDFchevron_right

Inflammatory status and lung function predict mortality in lung cancer screening participants

Anna Cantarutti

European Journal of Cancer Prevention, 2017

View PDFchevron_right

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Roberta Zappasodi

Journal for ImmunoTherapy of Cancer, 2016

View PDFchevron_right

Immunotherapeutic and their immunological aspects: Current treatment strategies and agents

Pratap Shankar

National Journal of Maxillofacial Surgery

View PDFchevron_right

Interleukin-2 Tickles T Cell Memory

Frederick Masson

Immunity, 2010

View PDFchevron_right

Clin-Immunotherapy/Biologic Therapies

John Bringas

Neuro-Oncology, 2012

View PDFchevron_right

Cancer Vaccines and Tumor Immunity

Veronica Preda

2007

View PDFchevron_right

Vaccines for Lung Cancer

Eric Toloza

Handbook of Cancer Vaccines, 2004

View PDFchevron_right

Lung cancer and Toll-like receptors

Silvana Morello

Cancer Immunology, Immunotherapy, 2011

View PDFchevron_right